Last updated on March 2018

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

Brief description of study

The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.

Clinical Study Identifier: NCT02860130

Contact Investigators or Research Sites near you

Start Over

Eric Judd, MD

University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Bijin Thajudeen, MD

University of Arizona
Tucson, AZ United States
  Connect »

Justin Belcher, MD

Yale University School of Medicine
New Haven, CT United States
  Connect »

Michael Connor, MD

Emory University
Atlanta, GA United States
  Connect »

Cybele Ghossein-Hoseen, MD

Northwestern University
Chicago, IL United States
  Connect »

Jason Stubbs, MD

University of Kansas Medical Center
Kansas City, KS United States
  Connect »

Javier Neyra, MD

University of Kentucky
Lexington, KY United States
  Connect »

Daniel Herr, MD

University of Maryland Medical Center
Baltimore, MD United States
  Connect »

Bradley Denker, MD

Beth Israel Deaconess (Harvard)
Boston, MA United States
  Connect »

Baxter Clinical Trials Disclosure Call ...

University of Mississippi Medical Center
Jackson, MS United States
  Connect »

Baxter Clinical Trials Disclosure Call ...

Cleveland Clinic
Cleveland, OH United States
  Connect »

Sean Bagshaw, MD

University of Alberta Hospital
Edmonton, AB Canada
  Connect »